Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis
European Respiratory Journal · 2025
DOI: 10.1183/13993003.01575-2024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Yet H Khor und 11 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Research@Alfred, School of Translational Medicine, Monash University, Melbourne, Australia yet.khor@monash.edu. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Pulmonary Fibrosis, Eligibility Determination, Patient Selection. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Boehringer Ingelheim, National Health and Medical Research Council.
Abstract (Originalsprache)
Background
Progressive pulmonary fibrosis (PPF) is of substantial interest for novel pharmacotherapy discovery, but little is known about clinical trial eligibility criteria. We evaluated eligibility criteria of PPF randomised controlled trials, their representativeness in registry patients, and forced vital capacity changes and mortality according to trial eligibility.
Methods
A systematic search was used to identify completed and in-progress phase 2 and 3 PPF randomised controlled trials. Common clinical trial eligibility criteria used in ≥60% of previous PPF randomised controlled trials were identified. The most common criteria for PPF used in randomised controlled trials (“trial-PPF criteria”) and the clinical practice guideline definition of PPF (“guideline-PPF criteria”) were both applied to patients enrolled in a prospective multicentre Canadian registry. Common trial eligibility criteria were tested for their frequency and association with health outcomes in registry patients who met trial-PPF and guideline-PPF criteria.
Results
10 different definitions of PPF were used in 16 randomised controlled trials. At the time of meeting PPF definitions, 50% of 864 patients with trial-PPF and 44% of 408 patients with guideline-PPF met the common trial eligibility criteria. For both definitions, trial-eligible patients had more rapid 1-year decline in forced vital capacity but better transplant-free survival than trial-ineligible patients. Patients with unclassifiable interstitial lung disease had a higher proportion of trial exclusion compared to those with connective tissue disease-associated interstitial lung disease and fibrotic hypersensitivity pneumonitis. Annual forced vital capacity decline (trial-PPF: −67 to −21 mL; guideline-PPF: −116 to −41 mL) and 1-year transplant-free survival (trial-PPF: 90.5–97.5%; guideline-PPF: 87–96.2%) varied in trial-eligible patients across interstitial lung disease subtypes.
Conclusions
Existing randomised controlled trials use a variety of definitions for PPF with eligibility criteria that have limited representativeness. Forced vital capacity decline and transplant-free survival vary according to trial eligibility and interstitial lung disease subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Respiratory Research@Alfred, School of Translational Medicine, Monash University, Melbourne, Australia yet.khor@monash.edu.
- Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia.
- Institute for Breathing and Sleep, Heidelberg, Australia.
- Faculty of Medicine, University of Melbourne, Melbourne, Australia.
- Department of Medicine, University of Calgary, Calgary, AB, Canada.
- Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
ORCID-Profile: Yet H Khor, Kerri A Johannson, Deborah Assayag, Martin Kolb
Förderung
- Boehringer Ingelheim
- National Health and Medical Research Council
Zitieren
APA
Khor, Y. H., Johannson, K. A., Marcoux, V., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Marinescu, D. C., Muller, N. L., Kolb, M., Ryerson, C. J., & CARE-PF Investigators (2025). Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis. European Respiratory Journal. https://doi.org/10.1183/13993003.01575-2024
Vancouver
Khor YH, Johannson KA, Marcoux V, Fisher JH, Assayag D, Manganas H, et al. Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis. European Respiratory Journal. 2025. doi:10.1183/13993003.01575-2024
BibTeX
@article{Khor2025,
author = {Khor, Yet H and Johannson, Kerri A and Marcoux, Veronica and Fisher, Jolene H and Assayag, Deborah and Manganas, Helene and Khalil, Nasreen and Marinescu, Daniel-Costin and Muller, Nestor L and Kolb, Martin and Ryerson, Christopher J and CARE-PF Investigators, CARE-PF Investigators},
title = {Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis},
journal = {European Respiratory Journal},
year = {2025},
doi = {10.1183/13993003.01575-2024}
}
EUVIMED